| Mon, 21 Sep 2020 23:14:31: | Viral vector manufacturer Vibalogics adds CEO to lead expansion, COVID-19 response
|
| Mon, 21 Sep 2020 16:25:38: | ESMO: Merck's Keytruda pushes for 2nd esophageal cancer nod with first-line survival win
|
| Mon, 21 Sep 2020 13:55:22: | Chinese customs raids J&J CAR-T partner Legend's office, puts new CEO under 'residential surveillance'
|
| Mon, 21 Sep 2020 13:51:31: | FiercePharmaPolitics—White House, pharma pricing talks fell apart over demand for 'Trump Cards': NYT
|
| Mon, 21 Sep 2020 06:00:42: | ESMO: Merck's Keytruda doubles 5-year survival rate for lung cancer patients
|
| Sun, 20 Sep 2020 11:45:18: | ESMO: Roche, after Tecentriq's ovarian cancer fail, banks hopes on final survival analysis
|
| Sat, 19 Sep 2020 12:14:49: | ESMO: New Trodelvy breast, bladder cancer data show why Gilead's going big for Immunomedics
|
| Fri, 18 Sep 2020 18:29:36: | ESMO: Pfizer, Merck KGaA's Bavencio comes up short against placebo in risky head and neck cancer trial
|
| Fri, 18 Sep 2020 16:53:29: | ESMO: Roche's mixed results put Tecentriq's triple-negative breast cancer use into question
|
| Fri, 18 Sep 2020 14:13:03: | ESMO: Lilly's Verzenio pressures Pfizer with practice-changing win in early breast cancer
|
| Fri, 18 Sep 2020 13:44:10: | Biogen stands to lose billions in Tecfidera sales next year, analyst says after new court ruling
|
| Fri, 18 Sep 2020 13:31:37: | ESMO: Regeneron and Sanofi gun for Libtayo in first-line NSCLC with fresh survival stats
|
| Fri, 18 Sep 2020 12:50:46: | Sanofi, GlaxoSmithKline score EU supply pact for 300M coronavirus shots
|
| Fri, 18 Sep 2020 08:29:50: | FiercePharmaAsia—Takeda's cell therapy center; Celltrion's COVID-19 antibody; Dr. Reddy's Revlimid deal
|
| Fri, 18 Sep 2020 07:21:42: | ESMO: Merck's Keytruda-chemo combo shows survival 'trend' but can't top chemo in bladder cancer
|
| Thu, 17 Sep 2020 23:23:45: | ESMO: AstraZeneca's targeted lung cancer med Tagrisso slashes CNS recurrence by 82%
|
| Thu, 17 Sep 2020 17:37:10: | ESMO: Novartis parses long-awaited survival data for breast cancer blockbuster hopeful Piqray
|
| Thu, 17 Sep 2020 15:09:02: | Moderna CEO expects to know by November whether coronavirus vaccine works: report
|
| Thu, 17 Sep 2020 15:00:33: | Pfizer plans DTC effort to pitch COVID-19 shot safety, joining a fall flurry of vaccine messaging
|
| Thu, 17 Sep 2020 14:11:49: | BioNTech buys Novartis plant for COVID-19 vaccine, eyes capacity of up to 750M doses
|
| Thu, 17 Sep 2020 13:02:21: | Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails
|
| Thu, 17 Sep 2020 01:37:04: | Merz signs actress and lifestyle maven Paltrow as new face of aesthetic injection Xeomin
|
| Wed, 16 Sep 2020 22:10:05: | Roche, already prepping 2021 launch, charts big expansion plans for Lucentis eye implant
|
| Wed, 16 Sep 2020 17:35:30: | Kodak execs didn't illegally trade stock while touting big move into pharma: report
|
| Wed, 16 Sep 2020 13:55:54: | Pfizer sees 'mostly mild to moderate' safety profile in phase 3 COVID-19 vaccine study
|
